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Left ventricular aneurysm (LVA) is defined as a localized area of myocardium with abnormal 
outward bulging and deformation during both systole and diastole. The rate of LVAs after AMI 
is approximately 3-15%.  
https://emedicine.medscape.com/article/164924-overview#a10 
LV thrombi are predominantly a complication of nonreperfused anterior wall STEMI, usually 
associated with prominent Q waves in the anterior electrocardiographic leads and anterior wall 
akinesia or dyskinesia on echocardiography.  
One of the most feared complications is the 
occurrence of thromboembolic events (mostly 
cerebrovascular accidents) due to left ventricular (LV) 
thrombus formation. The risk of LV thrombus 
formation is highest during the first 3 months 
following acute myocardial infarction, but the 
potential for cerebral emboli persists in the large 
population of patients with chronic LV dysfunction.  
OUR PATIENT 
•Patient K.V.S. 
• male  
•72 y. old 
•on pension 
•city resident  
of admission: 05 – September – 2015 
COMPLAINTS 
 
• Anxiety  
• General weakness 
• Trembling inside 
• Palpitation periodically 
• Dyspnea and chest pain exertional in nature (mild activity) 
ANAMNESIS MORBI 
- Arterial hypertension and CAD diagnosis were established 20 years ago. 
- Blood pressure levels usual are 170/90-100, receives constant therapy with ACE 
inhibitors 
- 1993 – history of MI. 
- Constant therapy with aspirin 75 mg/day around 5 years long 
- Felt worse 3 days before hospitalization, when appeared palpitation, trembling inside 
and anxiety, increased general weakness 
- Was administered by ambulance in cardiology department of 25 city hospital  
ANAMNESIS VITAE 
• Hereditary diseases are not identified 
• Allergic history is burdened: penicillin reaction 
• Childhood infections - no 
• Sexually transmitted diseases were denied 
• Smoker - no, do not abuse alcohol 
• CV disease family history: nothing 
OBJECTIVE STATUS 
- Conciseness - clear, state – moderate severe, body position - active 
- Patient can orientate himself in place, time, his personality 
- Pale skin and mucosae 
- Thyroid: not enlarged, soft 
- Musculoskeletal system – no changes 
- BR – 16-18 /min 
- Lung percussion: no clinically significant changes 
- Lung auscultation: hard breathing 
- Borders of the heart: left border – outside of midclavicular left line on 2 cm 
- Heart auscultation: arrhythmic, extrasystoles 2-3 in min, heart tones – muffled, diastolic soft 
murmur over apex. 
- Pulse – arrhythmic, 76 bts/min 
- BP 145 / 80 mm Hg 
- Abdomen: normal size, symmetric, unpainful 
- Liver: normal size, no pain during palpation in right hypochondrium 
- Spleen: normal 
- Pasternatsky symptom – negative from both sides 
- Edemas: absent 
09/10/17 Normal Range 
Hemoglobin, g/l  164 130 – 160 
Red blood cells, 1012 4.81 4.0 – 5.0  
Ht 47% 40-48% 
White blood cells, 109 4,4 4 - 9 
ESR, mm/h 8 1 -10 
Bands  3% 1.06 – 6% 
Segments  71% 47 – 72% 
Eosinophils  2% 0.5 – 5% 
Monocytes  3% 0.1 – 3% 
Lymphocytes  21% 19 – 37 % 
Platelets  264,6 180-320 
BLOOD COUNT 
Conclusion: no clinically important changes 
Conclusion: sinus rhythm, HR 98 bts, ventricular extrasystolic arrhythmia, ST-elevation in antero-lateral leads  without dynamics 
ECG 
Q 
BIOCHEMISTRY TEST DATA 
Patient’s ranges, N 
Glucose, mmol/l 6.1 3.38 – 5.55 
Total bilirubin, mkmol/l 21,4 8,6 – 25,5 
AST, mkmol/h*ml 0,80 0,1-0,445 
ALT, mkmol/h*ml 0,98 0,1-0,68 
Protrombin index, % 91 85-105 
Creatinine, mkmol/l 92 80 – 115 
K, mmol/l 5 3,5-5,1 
Mg, mmol/l 0,9 0,7-0,99 
Na, mmol/l 142 135-145 
Conclusion: liver cytolysis as long term aspirin treatment side-effect  
Patient’s ranges, N 
Total cholesterol, mmol/l 6.03 < 5.2 
VLDL, mmol/l 0.12 < 1.0 
LDL, mmol/l 4,19 < 3.5 
TAG, mmol/l 0,77 < 2.3 
HDL, mmol/l 1,49 ≥ 0.9 
Index of atherogenicity 3.37 < 3.0 
LIPID PROFILE 
Conclusion: dyslipidaemia 
HEART ULTRASOUND   
Aorta: dilated, cuspids are thickened. Ascending aorta – d 38 (20-37mm). Aortic regurgitation I degree. 
Tricuspid valve – no regurgitation. Pulmonary trunk valve – no regurgitation.  
Pressure in pulmonary trunk is 19,0 mm Hg (< 15). Mitral valve – cuspids are moderately thickened, movements of leaflets is 
in different direction, anterior cuspid in left atrium cavity during systole, regurgitation II degree.  
EF – 36% (N - 55 – 78%). FS – 41% (N - 28 – 44%). 
Left Ventricle: 
FDD – 53 mm (N – 35 – 55mm)  
FSD – 42 mm (N – 23 – 38 mm) 
Posterior wall thickness in systole– 12,2 mm (N – 6 – 13mm). 
Intraventricular septum size in diastole– 6,0 mm ( 6 – 11 mm)  
Additional chorda in LV cavity. In LV cavity situated round shape parietal thrombus 27*29 mm. 
Right Ventricle: 
Diameter – 28,1 mm (N – 9 – 26 mm)  
Wall thickness – 6,0 mm (N – 3 - 6 mm). 
Left atrium – enlarged – 44,1 mm in diameter ( N – till 38 mm) 
Right atrium – not enlarged, 36 mm(N – 25-37). Interatrial septum – not changed, no defects. 
 
Conclusion: Sclerotic changes of aorta. Aortic regurgitation I degree. Mitral regurgitation II degree. Akinesia of LV apical 
segments and intraventricular septum with systolic dysfunction of LV. Moderate dilation of left atrium. Chronic LV aneurism 
with mural thrombus (27*29 mm).  
COMPLETE DIAGNOSIS of our patient is: 
 
• Coronary Artery Disease: stable angina III functional class, postinfarction 
cardiosclerosis (1993). Chronic heart aneurism with mural thrombus.  
• Mitral regurgitation II degree, aortic regurgitation I degree.  
• Arterial Hypertension III degree, III stage, very high risk.  
• Ventricular extrasystolic arrhythmia.  
• HAS-BLED Score -3 points. 
• Chronic Heart Failure IIIC stage with left ventricle systolic dysfunction (EF – 
36%), III functional class by NYHA.  
MEDICATIONS PRESCRIBED IN 
HOSPITAL 
• perindopril 4 mg 1 time\day from admission 
• nebivolol 2,5 mg 1 time/day from admission 
• rosurvastatin 10 mg 1 time a day from admission 
• aspirin 100 mg 1 time daily from admission 
• fondaparinux 2,5 mg subcutaneously from admission 
• tiotriazolin (metabolic) 4,0 ml IV 1 time\day from admission 
OUR RECOMMENDATIONS: 
• Lifestyle interventions and risk factor control (BP control, diet, alcohol, and weight control, adherence 
to treatment) 
• An ACE-blockers is recommended and should be up-titrated to the maximum tolerated dose, in 
addition to a beta-blocker, for symptomatic patients with CHF with reduced ejection fraction (HFrEF) 
to reduce the risk of HF hospitalization and death.  
• A beta-blocker is recommended initially at a low dose with gradually up-titration to the maximum 
tolerated dose, in addition an ACE-Id or ARB if ACEIb is not tolerated or contraindicated, for patients 
with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death. Beta-blockers are 
also effective agents for angina control in our patient’s case. 
• Continuous rosurvastatin 10 mg treatment as the benefits of statins in secondary prevention have been 
demonstrated. 
• Our pt has moderate risk for major bleeding if aspirin therapy will not be continued, presence of LV 
protruding thrombus as the risk factor of systemic embolisation and the protective effect of mitral 
regurgitation present so aspirin therapy can be switched to warfarin therapy with INR control for 
better further thromboembolism prevention 
• Mineralocorticoid/aldosterone receptor antagonists are recommended in all symptomatic 
patients (despite treatment with an ACEI and a beta-blocker) with HFrEF and LVEF ≤35%. Can 
be avoided in our patient case as EF is 36%, but used as AH treatment as needed. 
CONCLUSION 
http://dx.doi.org/10.1016/j.mayocp.2015.02.008 
From one hand, for mural thrombi, once diagnosed, oral anticoagulant 
therapy is a matter of discussion with a low level of evidence and 
recommended being guided by repeated echocardiography and with 
consideration of bleeding risk and need for concomitant antiplatelet 
therapy. In other hand presence of LV protruding thrombus is a 
conditions that increase the risk of systemic embolisation in patients with 
LV thrombus. Decision about anticoagulant therapy should be taken 
individually based on each patient clinical situation and adjusted risk of 
bleeding vs possible thromboembolism. 
Ischemic LV Aneurysm and Anticoagulation: Is It the Clot or the Plot 
That Needs Thinning?  
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